Evidence map›Paper›PMID 38249451›Full record

ReviewFrontiers in microbiology2023

Role of probiotics in managing various human diseases, from oral pathology to cancer and gastrointestinal diseases.

Oana-Alina Petrariu, Ilda Czobor Barbu, Adelina-Gabriela Niculescu, Marian Constantin, Georgiana Alexandra Grigore, Roxana-Elena Cristian, Grigore Mihaescu, Corneliu Ovidiu Vrancianu

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 1 pooled it
26.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Oana-Alina PetrariuMicrobiology-Immunology Department, Faculty of Biology, University of Bucharest, Bucharest, Romania.
Ilda Czobor BarbuMicrobiology-Immunology Department, Faculty of Biology, University of Bucharest, Bucharest, Romania.
Adelina-Gabriela NiculescuThe Research Institute of the University of Bucharest, Bucharest, Romania.
Marian ConstantinThe Research Institute of the University of Bucharest, Bucharest, Romania.
Georgiana Alexandra GrigoreMicrobiology-Immunology Department, Faculty of Biology, University of Bucharest, Bucharest, Romania.
Roxana-Elena CristianThe Research Institute of the University of Bucharest, Bucharest, Romania.
Grigore MihaescuMicrobiology-Immunology Department, Faculty of Biology, University of Bucharest, Bucharest, Romania.
Corneliu Ovidiu VrancianuMicrobiology-Immunology Department, Faculty of Biology, University of Bucharest, Bucharest, Romania.
University of Bucharest · RONational Institute of Research and Development for Biological Sciences · ROAcademy of Romanian Scientists · RORomanian Academy · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The imbalance of microbial composition and diversity in favor of pathogenic microorganisms combined with a loss of beneficial gut microbiota taxa results from factors such as age, diet, antimicrobial administration for different infections, other underlying medical conditions, etc. Probiotics are known for their capacity to improve health by stimulating the indigenous gut microbiota, enhancing host immunity resistance to infection, helping digestion, and carrying out various other functions. Concurrently, the metabolites produced by these microorganisms, termed postbiotics, which include compounds like bacteriocins, lactic acid, and hydrogen peroxide, contribute to inhibiting a wide range of pathogenic bacteria. This review presents an update on using probiotics in managing and treating various human diseases, including complications that may emerge during or after a COVID-19 infection.

Indexed as

dysbiosisgut microbiotaintestinal barriermicrobiome therapeuticsprobiotics

Identifiers

PMID38249451
PMCPMC10797027
OpenAlexW4390611582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.